Proteasome Inhibition May Increase Alectinib Efficacy in ALK/TP53-Mutated NSCLC
MPR,
Concomitant ALK rearrangements and TP53 mutations were associated with worse alectinib therapy outcomes in patients with non-smal…
Concomitant ALK rearrangements and TP53 mutations were associated with worse alectinib therapy outcomes in patients with non-smal…
Concomitant ALK rearrangements and TP53 mutations were associated with worse alectinib therapy outcomes in patients with non-smal…
Most lung cancers are of a type called non-small-cell lung carcinoma (NSCLC). This type of cancer is relatively insensitive to…
Researchers at Kanazawa University report in Clinical Cancer Research that in the most common type of lung cancer, certain…